Our History

Founded in 2012 as a spin-off from Dalhousie University in Halifax, Nova Scotia, we are now preparing to study our lead products in humans for the first time

ABK Over the Years

2012

ABK Biomedical Founded

Founded at Dalhousie University in 2012, The Three Founders; Interventional Radiologist Robert Abraham, MD, and Material Scientists, Dr’s Daniel Boyd, and Sharon Kehoe, engineered and patented a new platform technology based on “x-ray visible” glass microspheres.

2015

Manufacturing

Production of proprietary glass microspheres began in Halifax, Nova Scotia.

Delivery System

1st Generation delivery system was developed for bland microspheres.

2018

Focus on Yttrium90 (Y90)

ABK’s proprietary glass microspheres were redesigned with a focus on Y90 radioembolization.

New Management Team

An experienced management team was hired under new CEO and President Mike Mangano.

2019

Raised $30M USD in Series B Funding

The largest medical device venture capital raise in Atlantic Canada is used to further develop Eye90 microspheres™, and Easi-Vue™ embolic microspheres.

Multi-year Strategic Partnership with MURR®

The Missouri University Research Reactor Center is the primary irradiation partner for ABK’s radioembolization products.

Y90 microsphere production

2020

Eye90™microspheres

Finalized design and completed pre-clinical testing for Eye90 microspheres™ technology.

Accelerated Manufacturing

Commissioned two new manufacturing and cleanroom facilities to accelerate device operations.

 

2021

Regulatory and Clinical Transition / Execution

ABK Biomedical anticipates initiating First in Man studies with Eye90 microspheres™ and plans to file a 510(k) with the FDA for Easi-Vue™ embolic microspheres in 2021.

MORE THAN JUST AN EMPLOYER

The ABK Biomedical Team

We are dedicated to encouraging a stimulating work environment offering an opportunity to significantly expand experience and skills by researching, developing, and commercializing cutting-edge medical device technologies with a mandate to effectively treat cancer.

ABK Biomedical is an equal opportunity employer offering competitive compensation packages.

ABK's Business Partners

ABK Biomedical is proud to partner with cutting-edge organizations and individuals with exceptional skills, scientific expertise, and the highest business ethics.

Investment Partners

Research Partners

Development Partners

Corporate Offices

Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada

T. 902.442.4009

 

Orange County Office
555 Corporate Drive 
Suite 105
Ladera Ranch, CA, 92694
USA

ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. ABK Biomedical inc. products are considered investigational products and are NOT FDA approved for use. Y90 radioembolization

(C) Copyright 2021 - All International Rights Reserved